Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.73 |
| ▸ | KDR | P35968 | 6/20 | 0.73 |
| ▸ | AXL | P30530 | 2/20 | 0.73 |
| ▸ | FLT3 | P36888 | 2/20 | 0.73 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.73 |
| ▸ | KIT | P10721 | 1/20 | 0.73 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.73 |
| ▸ | MST1R | Q04912 | 15/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | LYN | P07948 | 1/20 | 0.62 |
| ▸ | HCK | P08631 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | BCR | P11274 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.62 |
| ▸ | ABL2 | P42684 | 1/20 | 0.62 |
| ▸ | FRK | P42685 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514769 | 1.00 | MET (0.73) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL104989 | 0.96 | MET (0.67) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL2534615 | 0.94 | MET (0.65) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL2670680 | 0.94 | MET (0.64) | METKDRAXLFLT3NTRK1 | |
| Malic Acid SCHEMBL29910999 | 0.94 | MET (0.65) | METKDRAXLFLT3NTRK1 | |
| Malic Acid SCHEMBL29910932 | 0.94 | MET (0.65) | METKDRAXLFLT3NTRK1 | |
| Malic Acid SCHEMBL26110839 | 0.94 | MET (0.65) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL2670825 | 0.92 | MET (0.61) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL105538 | 0.90 | MET (0.64) | METKDRAXLFLT3NTRK1 | |
| SCHEMBL1479218 | 0.88 | MET (0.57) | METKDRAXLFLT3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4027999-B1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | MIRATI THERAPEUTICS INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-11787819-B2 | Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | MIRATI THERAPEPEUTICS, INC. (US) | 2023-10-17 | — | — | US | claimed |
| EP-4213844-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2023-07-26 | — | — | EP | claimed |
| US-20220402936-A1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. | 2022-12-22 | — | — | US | claimed |
| US-20220289760-A1 | CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. | 2022-09-15 | — | — | US | claimed |
| EP-4027999-A1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. (US) | 2022-07-20 | — | — | EP | claimed |
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2021-06-03 | — | — | US | claimed |
| WO-2021050580-A1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | claimed |
| EP-3773725-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | Loxo Oncology Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. | 2021-01-28 | — | — | US | claimed |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | LOXO ONCOLOGY, INC. (US) | 2020-07-28 | — | — | US | claimed |
| WO-2019191659-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | ARRAY BIOPHARMA, INC. | 2017-09-14 | — | — | US | claimed |
| EP-4027999-B1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | MIRATI THERAPEUTICS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12466838-B2 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | Mirati Therapeutics, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-12466838-B2 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | Mirati Therapeutics, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-2183254-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | MethylGene Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| WO-2009026717-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210164055-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | MET 220/4885KDR 661/4885AXL 1642/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | MET 1062/4885KDR 526/4885AXL 418/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MET 3/4885KDR 11/4885AXL 130/4885 |
| US-12466838-B2 | Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | ABL1, LCK, SRC | MET 148/4885KDR 262/4885AXL 57/4885 |
| US-20220289760-A1 | CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | LCK, MAP2K5, SRC | MET 14/4885KDR 733/4885AXL 206/4885 |
| US-20220402936-A1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | ABL1, LCK, SRC | MET 148/4885KDR 262/4885AXL 57/4885 |
| US-11787819-B2 | Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | LCK, MAP2K5, SRC | MET 14/4885KDR 733/4885AXL 206/4885 |
| US-20210023086-A1 | TREATMENT OF TRK-ASSOCIATED CANCERS | TP53, NCOA3, NCOA1 | MET 7/4885KDR 297/4885AXL 2198/4885 |
| US-20170260589-A1 | POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME | NTRK3, NTRK1, NTRK2 | MET 227/4885KDR 645/4885AXL 1509/4885 |
| US-10724102-B2 | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same | NTRK3, NTRK1, NTRK2 | MET 220/4885KDR 661/4885AXL 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.